{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:03:30Z","timestamp":1788404610059,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,29]]},"DOI":"10.7759\/cureus.41146","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T13:42:37Z","timestamp":1688046157000},"source":"Crossref","is-referenced-by-count":4,"title":["Successful Management of Kratom Use Disorder With Buprenorphine and Naloxone"],"prefix":"10.7759","author":[{"given":"Martin","family":"Arhin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Mobley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamad","family":"Hamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Remick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/968786","article-title":"Following \u201cThe Roots\u201d of kratom (Mitragyna speciosa): The evolution of an enhancer from a traditional use to increase work and productivity in Southeast Asia to a recreational psychoactive drug in Western countries","volume":"2015","author":"Cinosi E","year":"2015","unstructured":"Cinosi E, Martinotti G, Simonato P, et al.. Following \u201cThe Roots\u201d of kratom (Mitragyna speciosa): The evolution of an enhancer from a traditional use to increase work and productivity in Southeast Asia to a recreational psychoactive drug in Western countries. Biomed Res Int. 2015, 2015:968786. 10.1155\/2015\/968786","journal-title":"Biomed Res Int"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/medicines6010035","article-title":"Mitragyna speciosa: Clinical, toxicological aspects and analysis in biological and non-biological samples","volume":"6","author":"Meireles V","year":"2019","unstructured":"Meireles V, Rosado T, Barroso M, et al.. Mitragyna speciosa: Clinical, toxicological aspects and analysis in biological and non-biological samples. Medicines (Basel). 2019, 6:35. 10.3390\/medicines6010035","journal-title":"Medicines (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2280","article-title":"Kratom use and toxicities in the United States","volume":"39","author":"Eggleston W","year":"2019","unstructured":"Eggleston W, Stoppacher R, Suen K, Marraffa JM, Nelson LS. Kratom use and toxicities in the United States. Pharmacotherapy. 2019, 39:775-7. 10.1002\/phar.2280","journal-title":"Pharmacotherapy"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.107849","article-title":"Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic","volume":"208","author":"Garcia-Romeu A","year":"2020","unstructured":"Garcia-Romeu A, Cox DJ, Smith KE, Dunn KE, Griffiths RR. Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic. Drug Alcohol Depend. 2020, 208:107849. 10.1016\/j.drugalcdep.2020.107849","journal-title":"Drug Alcohol Depend"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.751656","article-title":"Kratom alkaloids: Interactions with enzymes, receptors, and cellular barriers","volume":"12","author":"Hanapi NA","year":"2021","unstructured":"Hanapi NA, Chear NJ, Azizi J, Yusof SR. Kratom alkaloids: Interactions with enzymes, receptors, and cellular barriers. Front Pharmacol. 2021, 12:751656. 10.3389\/fphar.2021.751656","journal-title":"Front Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-013-3195-5","article-title":"Role of kappa-opioid receptors in stress and anxiety-related behavior","volume":"229","author":"Van't Veer A","year":"2013","unstructured":"Van't Veer A, Carlezon WA Jr. Role of kappa-opioid receptors in stress and anxiety-related behavior. Psychopharmacology (Berl). 2013, 229:435-52. 10.1007\/s00213-013-3195-5","journal-title":"Psychopharmacology (Berl)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/11782218221095873","article-title":"Health effects associated with kratom (Mitragyna speciosa) and polysubstance use: A narrative review","volume":"16","author":"Striley CW","year":"2022","unstructured":"Striley CW, Hoeflich CC, Viegas AT, et al.. Health effects associated with kratom (Mitragyna speciosa) and polysubstance use: A narrative review. Subst Abuse. 2022, 16:11782218221095873. 10.1177\/11782218221095873","journal-title":"Subst Abuse"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2582","article-title":"Changing trends in the use of kratom (Mitragyna speciosa) in Southeast Asia","volume":"32","author":"Singh D","year":"2017","unstructured":"Singh D, Narayanan S, Vicknasingam B, Corazza O, Santacroce R, Roman-Urrestarazu A. Changing trends in the use of kratom (Mitragyna speciosa) in Southeast Asia. Hum Psychopharmacol. 2017, 32:e2582. 10.1002\/hup.2582","journal-title":"Hum Psychopharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-020-00151-x","article-title":"Kratom-pharmacology, clinical implications, and outlook: A comprehensive review","volume":"9","author":"Eastlack SC","year":"2020","unstructured":"Eastlack SC, Cornett EM, Kaye AD. Kratom-pharmacology, clinical implications, and outlook: A comprehensive review. Pain Ther. 2020, 9:55-69. 10.1007\/s40122-020-00151-x","journal-title":"Pain Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7556\/jaoa.2016.156","article-title":"Update on the pharmacology and legal status of kratom","volume":"116","author":"Prozialeck WC","year":"2016","unstructured":"Prozialeck WC. Update on the pharmacology and legal status of kratom. J Am Osteopath Assoc. 2016, 116:802-9. 10.7556\/jaoa.2016.156","journal-title":"J Am Osteopath Assoc"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/add.15082","article-title":"Prevalence and description of kratom (Mitragyna speciosa) use in the United States: A cross-sectional study","volume":"116","author":"Schimmel J","year":"2021","unstructured":"Schimmel J, Amioka E, Rockhill K, Haynes CM, Black JC, Dart RC, Iwanicki JL. Prevalence and description of kratom (Mitragyna speciosa) use in the United States: A cross-sectional study. Addiction. 2021, 116:176-81. 10.1111\/add.15082","journal-title":"Addiction"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/anatox\/35.4.242","article-title":"Unintentional fatal intoxications with mitragynine and O-desmethyltramadol from the herbal blend Krypton","volume":"35","author":"Kronstrand R","year":"2011","unstructured":"Kronstrand R, Roman M, Thelander G, Eriksson A. Unintentional fatal intoxications with mitragynine and O-desmethyltramadol from the herbal blend Krypton. J Anal Toxicol. 2011, 35:242-7. 10.1093\/anatox\/35.4.242","journal-title":"J Anal Toxicol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.20r02770","article-title":"Kratom: An emerging issue and need for regulations in the United States","volume":"23","author":"Shah K","year":"2021","unstructured":"Shah K, Tankersley W, Mekala H. Kratom: An emerging issue and need for regulations in the United States. Prim Care Companion CNS Disord. 2021, 23:26032. 10.4088\/PCC.20r02770","journal-title":"Prim Care Companion CNS Disord"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.765917","article-title":"Searching for a signal: Self-reported kratom dose-effect relationships among a sample of US adults with regular kratom use histories","volume":"13","author":"Smith KE","year":"2022","unstructured":"Smith KE, Rogers JM, Dunn KE, Grundmann O, McCurdy CR, Schriefer D, Epstein DH. Searching for a signal: Self-reported kratom dose-effect relationships among a sample of US adults with regular kratom use histories. Front Pharmacol. 2022, 13:765917. 10.3389\/fphar.2022.765917","journal-title":"Front Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.19nr02507","article-title":"Kratom (Mitragyna speciosa): Friend or foe?","volume":"22","author":"Sethi R","year":"2020","unstructured":"Sethi R, Hoang N, Ravishankar DA, McCracken M, Manzardo AM. Kratom (Mitragyna speciosa): Friend or foe?. Prim Care Companion CNS Disord. 2020, 22:19nr02507. 10.4088\/PCC.19nr02507","journal-title":"Prim Care Companion CNS Disord"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/167289-successful-management-of-kratom-use-disorder-with-buprenorphine-and-naloxone","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T15:01:24Z","timestamp":1707490884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/167289-successful-management-of-kratom-use-disorder-with-buprenorphine-and-naloxone"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.41146","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,29]]}}}